CCA
RANI icon

Cygnus Capital Advisors’s Rani Therapeutics RANI Stock Holding History

Cygnus Capital Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89K Buy
116,432
+783
+0.7% +$694 0.06% 57
2026
Q1 		$85K Buy
+115,649
New +$148K 0.06% 64

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cygnus Capital Advisors's RANI Position: Q2 2026 in Review

Cygnus Capital Advisors increased its Rani Therapeutics (RANI) stake by 0.68% in Q2 2026, buying an estimated $694 and bringing the position to 116,432 shares worth $89K. The position accounts for 0.06% of the portfolio, ranked #57.

Cygnus Capital Advisors first reported a position in RANI in Q1 2026 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Cygnus Capital Advisors held 116,432 shares of Rani Therapeutics worth $89K as of Q2 2026.
  • Cygnus Capital Advisors bought 783 Rani Therapeutics shares in Q2 2026, an estimated $694.
  • Rani Therapeutics made up 0.06% of Cygnus Capital Advisors's portfolio in Q2 2026, its #57 holding.
  • Cygnus Capital Advisors first reported a position in Rani Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.